Mer­ck dis­card jumps straight to the top of the chart of the most ex­pen­sive drugs in the US at $1M-plus

Back late last fall, when Eiger Phar­ma­ceu­ti­cals $EIGR com­plet­ed its vic­to­ry lap with an old Mer­ck dis­card it had de­vel­oped for rare cas­es of prog­e­ria, the com­pa­ny told re­porters that it was think­ing of pric­ing the new­ly dubbed Zok­in­vy at the usu­al rate re­served for ul­tra rare dis­eases. Mer­ck aban­doned the drug years ago af­ter giv­ing up on a can­cer in­di­ca­tion, and let Eiger have it for Prog­e­ria sev­er­al years ago with­out tack­ing on any mile­stones in the deal.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.